CUTIVATE Drug Patent Profile

Which patents cover Cutivate, and what generic alternatives are available?

Cutivate is a drug marketed by Fougera Pharms and is included in three NDAs.

The generic ingredient in CUTIVATE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-three suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cutivate

A generic version of CUTIVATE was approved as fluticasone propionate by ENCUBE on May 14^th, 2004.

Summary for CUTIVATE

US Patents:	0
Applicants:	1
NDAs:	3

Paragraph IV (Patent) Challenges for CUTIVATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CUTIVATE	Lotion	fluticasone propionate	0.05%	021152	1	2008-07-28

US Patents and Regulatory Information for CUTIVATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fougera Pharms	CUTIVATE	fluticasone propionate	CREAM;TOPICAL	019958-001	Dec 18, 1990		DISCN	Yes	No
Fougera Pharms	CUTIVATE	fluticasone propionate	LOTION;TOPICAL	021152-001	Mar 31, 2005		DISCN	Yes	No
Fougera Pharms	CUTIVATE	fluticasone propionate	OINTMENT;TOPICAL	019957-001	Dec 14, 1990		DISCN	Yes	No

International Patents for CUTIVATE

See the table below for patents covering CUTIVATE around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	0024401
France	2485542
Hungary	0104251
Spain	518161
Israel	142471
Ireland	51394	ANDROSTANE CARBOTHIOATES
Australia	6729881

Supplementary Protection Certificates for CUTIVATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527

CUTIVATE: Investment Fundamentals and Patent Landscape Analysis

Last updated: February 19, 2026

CUTIVATE (fluticasone propionate) is a topical corticosteroid used to treat inflammatory skin conditions. The investment outlook for CUTIVATE is influenced by market demand for dermatological treatments, competitive pressures from generic alternatives and newer therapies, and its patent protection status.

What is the Current Market Positioning of CUTIVATE?

CUTIVATE's market position is established in the topical corticosteroid segment. Its efficacy in treating conditions like eczema and psoriasis drives demand. However, the market is characterized by high competition from both branded and generic products.

• Primary Indications: Eczema (atopic dermatitis), psoriasis, contact dermatitis, seborrheic dermatitis.
• Formulations: Cream and ointment.
• Mechanism of Action: Fluticasone propionate is a potent synthetic corticosteroid that suppresses the release of inflammatory mediators. It exhibits anti-inflammatory, antipruritic, and vasoconstrictive effects.
• Market Share: While specific proprietary data is unavailable, CUTIVATE holds a consistent share within the topical corticosteroid market, often competing directly with other potent to very potent agents such as betamethasone dipropionate and clobetasol propionate [1].

What is the Patent Landscape for CUTIVATE?

The patent landscape for CUTIVATE is complex, involving both composition of matter patents and formulation patents. The original composition of matter patents for fluticasone propionate have expired, paving the way for generic competition. However, specific formulations and delivery systems may still hold patent protection.

• Composition of Matter Patent: The original patent protecting fluticasone propionate as a chemical entity has expired. This is a standard lifecycle for pharmaceutical compounds.
• Formulation Patents: Patents related to specific cream or ointment formulations that enhance stability, penetration, or patient compliance may still be active. These patents are crucial for maintaining market differentiation and potentially extending exclusivity for branded versions. For example, patents might cover specific excipients, emulsification systems, or methods of manufacturing that contribute to the drug's performance [2].
• Exclusivity Periods: Beyond patent expiry, regulatory exclusivities (e.g., Hatch-Waxman Act in the U.S.) can provide periods where generic manufacturers cannot obtain approval. These are distinct from patent protection.
• Litigation: The expiry of key patents often leads to patent litigation as generic companies seek to launch their products and brand manufacturers defend their remaining intellectual property [3].

What are the Key Competitive Threats to CUTIVATE?

CUTIVATE faces significant competitive threats from multiple fronts, including generic versions of itself, other branded topical corticosteroids, and newer therapeutic modalities.

Generic Competition

• Impact: The availability of generic fluticasone propionate significantly erodes the market share and pricing power of branded CUTIVATE. Generic manufacturers typically offer their products at a substantially lower price point.
• Timeline: Generic entry typically begins once primary composition of matter and relevant formulation patents expire or are successfully challenged. This often leads to a rapid decline in the branded product's revenue.
• Market Dynamics: In many markets, generic fluticasone propionate is widely available and prescribed interchangeably with the branded product due to similar efficacy and lower cost.

Other Topical Corticosteroids

• Potency Spectrum: CUTIVATE is generally classified as a potent topical corticosteroid (Group 2 or 3, depending on formulation and regulatory jurisdiction). It competes directly with other corticosteroids within this potency class, such as:
  • Betamethasone Dipropionate: Available in various strengths and formulations, often with comparable efficacy.
  • Clobetasol Propionate: A very potent corticosteroid, often used for more severe or resistant conditions, representing a higher tier of competition for severe cases.
  • Mometasone Furoate: Another potent corticosteroid with a well-established market presence.
• Dosing and Formulation Advantages: Competitors may offer formulations with perceived advantages, such as better cosmetic feel, enhanced penetration, or specific preservative systems that appeal to prescribers and patients.

Non-Steroidal Therapies and Biologics

• Emerging Treatments: The dermatological landscape has seen innovation with the development of non-steroidal topicals and systemic biologics. These treatments, while often more expensive, offer alternatives for patients who do not respond to or tolerate corticosteroids, or for whom long-term corticosteroid use is undesirable.
  • Topical Calcineurin Inhibitors: Tacrolimus and pimecrolimus are non-steroidal options used for sensitive areas or for patients requiring long-term management.
  • JAK Inhibitors (Topical and Systemic): Ruxolitinib cream (Opzelura) and oral JAK inhibitors are new classes of drugs for atopic dermatitis and psoriasis, offering different mechanisms of action.
  • Biologics: Systemic biologic therapies (e.g., adalimumab, secukinumab, dupilumab) are used for moderate-to-severe psoriasis and atopic dermatitis and represent a significant competitive force, particularly for patients with widespread or severe disease [4].
• "Steroid-Sparing" Approach: The increasing emphasis on reducing long-term corticosteroid use due to side effects (e.g., skin thinning, striae, tachyphylaxis) favors the adoption of alternative therapies, particularly for chronic conditions.

What is the Regulatory Status and Market Access for CUTIVATE?

The regulatory status and market access for CUTIVATE are governed by pharmaceutical regulations in different countries and the reimbursement policies of healthcare payers.

• Approvals: CUTIVATE (fluticasone propionate topical) has received approval from major regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
• Prescription Status: It is a prescription-only medication in most jurisdictions due to its potency and potential side effects.
• Reimbursement: Reimbursement policies vary by country and by insurance provider. Generally, topical corticosteroids are a well-established class of drugs and are often covered. However, formulary restrictions, prior authorization requirements, and step-therapy protocols can influence market access, particularly for branded products facing generic competition. The cost-effectiveness of generic fluticasone propionate often influences payer decisions.
• Labeling and Warnings: Regulatory agencies mandate specific labeling regarding potential side effects, usage duration, and contraindications, which can influence prescriber confidence and patient adherence.

What are the Financial Projections and Investment Considerations for CUTIVATE?

Investment considerations for CUTIVATE are primarily tied to the sales trajectory of the branded product versus the market penetration of its generics.

• Revenue Decline: The primary financial projection for the branded CUTIVATE is a continued revenue decline due to generic erosion. This is a predictable pattern for off-patent drugs.
• Generic Market Growth: The investment thesis for generic fluticasone propionate would focus on market share capture and volume sales. Profitability for generic manufacturers relies on efficient manufacturing and distribution.
• Branded Product Strategy: For the branded product manufacturer, strategies to mitigate revenue loss may include:
  • Portfolio Management: Shifting focus to newer, patented assets.
  • Lifecycle Management: Exploring new indications or improved formulations, though this is more challenging for older, well-established molecules.
  • Geographic Focus: Maintaining sales in markets with slower generic uptake or where brand loyalty is higher.
• Investment Risks:
  • Competition Intensification: Increased number of generic entrants.
  • Pricing Pressures: Aggressive pricing by generics and potential payer mandates.
  • Emergence of Superior Therapies: Further adoption of non-steroidal or biologic treatments.
  • Patent Litigation Outcomes: Unfavorable rulings could accelerate generic launches.
• Investment Opportunities:
  • Generic Manufacturers: Investing in companies with strong generic portfolios, including fluticasone propionate.
  • Companies Developing Novel Dermatological Therapies: Investing in companies with late-stage pipeline assets that address unmet needs in inflammatory skin diseases, offering long-term growth potential beyond corticosteroid limitations.

Key Takeaways

CUTIVATE's investment profile is characterized by the mature lifecycle of a topical corticosteroid. While its efficacy remains a driver of demand for fluticasone propionate, the expiry of primary patents has opened the door for significant generic competition. This competition directly impacts the revenue potential of branded CUTIVATE, leading to a projected decline. Investment opportunities exist in generic manufacturers capitalizing on volume sales or in companies developing next-generation dermatological treatments that address the limitations and side effects associated with corticosteroids. The evolving landscape of non-steroidal and biologic therapies further influences market dynamics, presenting both challenges and opportunities for stakeholders.

Frequently Asked Questions

1. When did the primary composition of matter patents for fluticasone propionate expire? The original composition of matter patents for fluticasone propionate have expired, with key patents lapsing in the early 2000s in major markets like the United States. This allowed for the introduction of generic fluticasone propionate.

2. Are there any remaining formulation patents that could provide exclusivity for CUTIVATE? While composition of matter patents have expired, specific formulation patents for CUTIVATE's cream or ointment may still be active in certain jurisdictions. These patents would protect unique aspects of the drug's delivery system, stability, or manufacturing process, potentially offering limited market differentiation.

3. What is the typical market impact of generic fluticasone propionate on branded CUTIVATE sales? Upon the entry of generic fluticasone propionate, branded CUTIVATE typically experiences a significant and rapid decline in sales and market share. This is driven by the substantial price difference between branded and generic products.

4. How do newer non-steroidal and biologic therapies for inflammatory skin conditions affect the market for CUTIVATE? Newer non-steroidal and biologic therapies offer alternatives to corticosteroids, particularly for patients with moderate-to-severe or chronic conditions who may experience side effects from long-term steroid use. This trend shifts prescribing patterns and reduces the reliance on traditional topical corticosteroids like CUTIVATE for certain patient populations.

5. What are the primary investment considerations for companies holding or manufacturing CUTIVATE? For branded CUTIVATE manufacturers, investment considerations focus on managing the decline in sales through lifecycle management strategies or by prioritizing newer, patented assets. For generic manufacturers, the investment revolves around efficient production, market penetration, and volume sales of fluticasone propionate.

Citations

[1] Ghadially, R. (2022). Topical Corticosteroids. In E. A. Goldman & A. P. Vleugels (Eds.), Dermatologic Surgery (pp. 128-133). Elsevier.

[2] Falla, T. J., & Mota, J. C. (2009). Patent Protection for Pharmaceutical Products. In The Pharmaceutical Journey: Development to Market (pp. 19-36). Academic Press.

[3] Sampat, M., & Swartz, P. (2017). The Impact of Patent Expirations on Pharmaceutical Sales. International Journal of Health Policy and Management, 6(3), 159–165.

[4] National Eczema Association. (n.d.). Treatments. Retrieved from https://nationaleczema.org/eczema-treatment/